Cyclopropane Fatty Acid PPAR Modulators With Lower Monitoring Burden
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing synthetic peroxisome proliferator-activated receptor (PPAR) ligands face safety concerns, high costs, and the need for liver function monitoring, limiting their widespread use for conditions like type 2 diabetes and metabolic disorders.
Innovation Solution
Utilization of bacteria-derived cyclopropane fatty acids (CpFAs) with specific structures, such as cis-11,12-methylene-pentadecanoic acid and cis-13,14-methylene-heptadecanoic acid, as PPAR ligands, which can be administered orally or topically to modulate PPAR α, δ, and/or γ, addressing various health conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If synthetic PPAR ligands are used to treat metabolic disorders and type 2 diabetes, then therapeutic efficacy is improved, but safety concerns and high costs worsen
Solution Approach 1:
The patent employs naturally occurring cyclopropane fatty acids (CpFAs) as PPAR ligands, replacing expensive synthetic drugs with naturally derived compounds that may have better safety profiles and lower costs. The CpFAs are obtained from bacterial fermentation or plant sources, providing a more economical and safer alternative to conventional synthetic PPAR agonists like thiazolidinediones.
Solution Approach 2:
The patent modifies the chemical structure of fatty acids by introducing cyclopropane rings at specific positions (Delta-9, Delta-11, or Delta-13) to create CpFA ligands with optimized PPAR binding affinities. This structural parameter change enables the compounds to activate PPARα, PPARδ, and PPARγ with high efficacy while maintaining natural metabolite characteristics that improve safety.
2Reliability
If synthetic PPAR ligands are used for treatment, then metabolic health is improved, but the need for liver function monitoring increases
Solution Approach 1:
The patent uses naturally occurring CpFAs that metabolize through conventional fatty acid oxidation pathways, eliminating the need for specialized monitoring systems. The compounds are processed by the body's existing enzymatic machinery (beta-oxidation), requiring no additional monitoring infrastructure compared to synthetic ligands that may require liver function testing and other surveillance measures.
3Object-affected harmful factors
If bacteria-derived cyclopropane fatty acids are used as PPAR ligands, then safety and cost are improved, but binding affinity and metabolic activity must be optimized
Solution Approach 1:
The patent systematically varies the position of cyclopropane ring introduction (Delta-9, Delta-11, or Delta-13) and adjusts the carbon chain length (C16-C24) to optimize PPAR binding affinity. This structural parameter optimization ensures high therapeutic efficacy while maintaining the safety and cost advantages of natural CpFA derivatives.
Solution Approach 2:
The patent develops CpFA ligands that can activate multiple PPAR isoforms (PPARα, PPARδ, and PPARγ) simultaneously or selectively, providing multi-functional therapeutic effects. This universality allows a single compound class to address multiple metabolic disorders through different PPAR pathways, enhancing binding affinity across various tissue types and physiological contexts.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
CpFAs effectively manage conditions like diabetes, metabolic disorders, and cardiovascular diseases by promoting metabolic health, improving insulin sensitivity, and reducing lipotoxicity without the drawbacks of synthetic ligands.
Implementation Method 1
cyclopropane fatty acids (CpFAs) having an affinity for binding peroxisome proliferator-activated receivers (PPARs)
Data Source
AI summary
A compound having the structure of Formula I: wherein m=2 and n is an odd-number between 4 and 20, or a derivative thereof, or a salt, or a prodrug thereof, and a compound having the structure of Formula II: wherein m and n are independently an integer between 2 and 20, or a derivative thereof, or a salt, or a prodrug thereof are described. Compositions and methods of use of the compounds for therapeutically modulating peroxisome proliferator-activated receptors (PPARs) are also provided